KRAS and colorectal carcinoma: Towards predicting clinical outcome in clinical trials, we hypothesized that [18F]FSPG PET could predict response to combined glutaminase and EGFR inhibition in WT KRAS CRC, a regimen currently being explored in a clinical trial (NCT 03263429).